Protara Therapeutics, Inc. (NASDAQ: TARA ) shares are down during Tuesday’s premarket session following the release of updated interim results from the ADVANCED-2 trial of TARA-002, a treatment for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC).
Bladder Cancer Data Shows Response Rate Of 66%
The interim analysis from 35 evaluable participants revealed a 68.2% complete response rate at six months for the BCG-Unresponsive cohort, with no Grade 3 or greater treatment-related adverse events reported.
The complete response (CR) rate at any time was 65.7%.
Among responders, the Kaplan-Meier (KM) estimated probability of maintaining a CR for six months was 71.1%.
100% maintained their complete response from nine to 12 months, and 61.5% of re-induced patients converted to a CR at six months.
In the BCG-naïve cohort, the interim analysis of 27 patients showed a complete response rate of 72.4% at any time, 66.7% at six months, and 57.9% (11 of 19) at 12 months.
Among responders, the KM estimated probability of maintaining a CR for six months was 73.1%, and 100% (11 of 11) maintained their CR from nine to 12 months.
66.7% (4 of 6) of re-induced patients converted to a CR at six months.
Protara expects to complete enrollment of this cohort in the second half of 2026, indicating a promising outlook for TARA-002’s development.
The results highlight TARA-002’s potential as a significant treatment option, particularly given the favorable safety and tolerability profile observed in the trial.
Technical Analysis
Currently, TARA is trading 12.65% below its 20-day simple moving average (SMA), indicating a bearish short-term trend. Over the past 12 months, shares have fluctuated between a high of $7.82 and a low of $2.77, and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, reflecting neutral territory, while MACD is not available for analysis. The absence of a clear MACD signal suggests a lack of momentum in either direction at this time.
The combination of neutral RSI and no MACD data indicates mixed momentum for TARA, suggesting that traders should exercise caution.
Key Resistance: $7.50 Key Support: $6.00Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $27.69. Recent analyst moves include:
HC Wainwright & Co.: Buy (Maintains Target to $23.00) (Feb. 10) Piper Sandler: Initiated with Overweight (Target $24.00) (Jan. 7) HC Wainwright & Co.: Buy (Maintains Target to $23.00) (Dec. 3, 2025)TARA Price Action: Protara Therapeutics shares were down 7.94% at $6.84 during premarket trading on Tuesday, according to Benzinga Pro data .
Photo by Aunt Spray via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Biotech News Health Care Top Stories Movers General benzai why it's moving